CC
CYTK icon

Curian Capital’s Cytokinetics CYTK Stock Holding History

Curian Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-63,877
Closed -$415K – 602
2013
Q4 		$415K Sell
63,877
-652
-1% -$4.28K 0.01% 518
2013
Q3 		$488K Buy
64,529
+36,613
+131% +$393K 0.01% 511
2013
Q2 		$323K Buy
+27,916
New +$220K 0.01% 535

Other funds holding CYTK

LPLP
Lansdowne Partners Limited Partnership London, United Kingdom $11.9B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Curian Capital's CYTK Position: Q1 2014 in Review

Curian Capital sold out of Cytokinetics (CYTK) in Q1 2014, closing a stake of 63,877 shares — an estimated $415K sold.

Curian Capital first reported a position in CYTK in Q2 2013 and held it in 3 quarters. The position peaked at $488K in Q3 2013. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2014.

  • Curian Capital reported no remaining Cytokinetics position as of Q1 2014 after selling out during the quarter.
  • Curian Capital sold 63,877 Cytokinetics shares in Q1 2014, an estimated $415K.
  • Curian Capital first reported a position in Cytokinetics in Q2 2013 and held it in 3 quarters.
  • Curian Capital's Cytokinetics position peaked at $488K in Q3 2013.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2014.

Based on Curian Capital's 13F filing for Q1 2014, filed 12 May 2014.